Famar to acquire Roche's Leganes site

Site provides Famar with capacities and expertise in the production of solid dosage forms with high-potency APIs, which represents new technology for the company.

Famar is a leading contract manufacturing rganization to the pharmaceutical and health and beauty markets, and ranked amongst the top 5 in this sector. Presently, it has an existing network of 11 manufacturing sites in Europe, which supply a wide range to the industry, serving most international markets, with a broad customer base.

The Leganes site is modern, well equipped and is approved for worldwide supply. It provides Famar with capacities and expertise in the production of solid dosage forms with high-potency active pharmaceutical ingredients, which represents new technology for the company and adds to Famar's technology portfolio in solid dosage formulations.

Because the Leganes site is FDA certified, it will give Famar access to the US market, which Famar anticipates will help to accelerate growth. By early 2017, Famar is expected to have two FDA approved sites in their global network, the other one is based in Canada.